INTERNATIONAL CONSENSUS TO DEFINE OUTCOMES FOR TRIALS OF CHEMORADIOTHERAPY FOR ANAL CANCER (CORMAC-2): DEFINING THE OUTCOMES FROM THE CORMAC CORE OUTCOME SET

Summary: Variation in outcomes definitions and reporting limit the utility of clinical trial results.The Core Outcome Research Measures in Anal Cancer (CORMAC) project developed a core outcome set (COS) for chemoradiotherapy trials for anal squamous cell carcinoma (ASCC) Myrrh Gum through an international healthcare professional and patient consens

Madam, Acute Intermittent Porphyria (AIP) is an autosomal dominant disorder that results from a defect in the enzyme named porphobilinogen deaminase.1 It is symptomatic porphyria, involving the accumulation of porphyrins and porphyrin precursors due to impaired conversion in haeme synthesis.Acute Intermittent Porphyria is clinically characterized b